Location History:
- Puteaux, FR (1997 - 1999)
- Villeneuve D'Ascq, FR (2003)
Company Filing History:
Years Active: 1997-2003
Title: Innovations by Dominique Manechez: A Focus on Peptide Compounds
Introduction
Dominique Manechez, an accomplished inventor based in Puteaux, France, has made significant contributions to the field of medicinal chemistry. With a portfolio of four patents to his name, he has been at the forefront of developing innovative peptide compounds and imidazoline derivatives, contributing to advancements in drug development.
Latest Patents
Manechez's latest patents include groundbreaking work on peptide compounds that are analogues of glucagon-like peptide-1 (7-37). His research delves into imidazoline compounds as well, particularly a compound of formula (I), where R is specified in the accompanying description. These compounds and their isomers, along with their pharmaceutically acceptable acid addition salts, have shown promise as useful ligands for imidazoline receptors, highlighting their potential applications in therapeutic settings.
Career Highlights
Throughout his career, Dominique Manechez has collaborated with notable companies in the pharmaceutical industry, including Adir Et Compagnie and Les Laboratoires Servier. His innovative work has contributed to the development of new medicinal products that address various health conditions.
Collaborations
Manechez has worked alongside esteemed colleagues such as Pierre Renard and Daniel-Henri Caignard. These collaborations have fostered a dynamic exchange of ideas and expertise, further enhancing the impact of their collective research on the field of medicinal compounds.
Conclusion
Dominique Manechez exemplifies the spirit of innovation in medicinal chemistry through his patents and collaborations. His ongoing work continues to pave the way for novel therapeutic agents, contributing significantly to advancements in healthcare and pharmacology. As he progresses in his career, the scientific community looks forward to his future inventions and patents that will further the field.